The MDCG, composed of competent authority representatives, issues numbered guidance documents (MDCG 2019-x, MDCG 2021-x, etc.) covering classification, clinical evaluation, vigilance, software, AI, and many other MDR/IVDR topics. The Medical Device Coordination Group is set up under MDR Article 103 and consists of representatives from each EU member state, chaired by the European Commission. It works through subgroups on topics such as clinical investigation, notified bodies, borderline products, IVDs, new technologies and cybersecurity. MDCG guidance documents are not legally binding but are widely used by notified bodies and competent authorities.

Why it matters

MDCG documents are not legally binding but set the de-facto interpretive baseline for Notified Bodies and competent authorities; ignoring them is risky.

Common pitfalls

•Ignoring MDCG guidance can lead to non-conformities during audits or market access delays, even though the guidance is not legally binding.
•Misinterpreting the scope or applicability of a specific MDCG document can result in misallocation of resources or incomplete compliance efforts.
•Failing to track updates or new MDCG documents can leave a manufacturer unaware of evolving regulatory expectations.
•Assuming national competent authorities will always align their interpretation perfectly with MDCG guidance without further clarification can lead to errors.
•Treating MDCG guidance as optional rather than an integral part of interpreting and applying the MDR/IVDR is a common pitfall.

Sources

MDCG Guidance · European Commission
RAPS Regulatory Focus · RAPS
FDA - Medical Devices · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.